Andy Darlington: Randomized Evidence for Catheter-Based Treatment of Intermediate-High-Risk PE
Andy Darlington, Global Partnerships Manager of Medical Devices at Radcliffe Group, shared a post on LinkedIn:
“In this clip, Prof Lukas Hobohm reviews the findings from the HI-PEITHO randomised controlled trial.
The trial compared EKOS plus anticoagulation with anticoagulation alone in 544 patients with intermediate-high-risk PE, assessing whether intervention could reduce early PE-related complications.
The discussion explores the reduction in the composite outcome of PE-related mortality, cardiopulmonary decompensation or PE recurrence within seven days, alongside findings on major bleeding and hospital length of stay.
Watch the clip below for insights into how randomised evidence is shaping treatment strategies for intermediate-high-risk PE.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Sep 15, 2026, 15:29Abdul Muqtadir Abbasi: Recognizing Thalassemia Trait Is Essential for Every Physician
-
Sep 15, 2026, 15:17Shehab Mohamed: A New Regional Consensus on HLH Diagnosis and Management
-
Sep 15, 2026, 15:17Sheharyar Raza: Managing Randomness in Artificial Intelligence for Transfusion Medicine
-
Sep 15, 2026, 15:00Sarah Wachtman: Modeling AAV-Based Gene Therapy for Hemophilia A Using Pediatric Liver Organoids
-
Sep 15, 2026, 15:00Ashenafi Tazebew Amare: From Blood Donation to Innovation and Patient Access
-
Sep 15, 2026, 14:56Glanzmann Thrombasthenia Beyond Platelet Transfusion
-
Sep 15, 2026, 14:55Christina Pohlman: The Hidden Complexity of Warfarin Therapy in APS
-
Sep 15, 2026, 14:44Consuela A. Albright: Building a More Connected Sickle Cell Care System
-
Sep 15, 2026, 14:43Andrew Jackson: Cyanosis as a Clue to Central Venous Obstruction